The domestic equity benchmarks continued to trade with major losses in early afternoon trade. The Nifty slipped below the 24,250 mark. Pharma shares slipped after advancing in the past two consecutive trading sessions. At 12:30 IST, the barometer index, the S&P BSE Sensex dropped 760.75 points or 0.95% to 79,617.20. The Nifty 50 index fell 260.55 points or 1.06% to 24,223.40. In the broader market, the S&P BSE Mid-Cap index fell 0.38% and the S&P BSE Small-Cap index added 0.05%. The market breadth was positive. On the BSE, 1,952 shares rose and 1,876 shares fell. A total of 137 shares were unchanged. Derivatives: The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, added 2.52% to 15.24. The Nifty 28 November 2024 futures were trading at 24,308, at a premium of 84.6 points as compared with the spot at 24,223.40. The Nifty option chain for the 28 November 2024 expiry showed maximum Call OI of 32.2 lakh contracts at the 25,000 strike price. Maximum Put OI of 40.4 lakh contracts were seen at 23,000 strike price. Buzzing Index: The Nifty Pharma index fell 1.73% to 22,523.05. The index rose 0.61% for the past two trading session. Glenmark Pharmaceuticals (down 5.5%), Ajanta Pharma (down 4.29%), Aurobindo Pharma (down 2.8%), Gland Pharma (down 2.37%), Alkem Laboratories (down 2.24%), Sun Pharmaceuticals Industries (down 2.18%), Lupin (down 1.72%), Zydus Lifesciences (down 1.6%), Cipla (down 1.44%) and Torrent Pharmaceuticals (down 1.41%) slipped. On the other hand, Biocon (up 0.9%), Granules India (up 0.73%) advanced. Stocks in Spotlight : Apollo Hospitals Enterprise jumped 6.20% after the company reported 62.64% surge in consolidated net profit to Rs 378.8 crore in Q2 FY25 as against Rs 232.9 crore posted in Q2 FY24. Revenue from operations increased 15.31% year on year (YoY) to Rs 5,589.3 crore in the quarter ended 30 September 2024. Kirloskar Ferrous Industries slipped 1.84% after the company reported 4.93% decline in consolidated net profit to Rs 77.64 crore in Q2 FY25 as compared to Rs Rs 81.67 crore in Q2 FY24. TeamLease Services declined 5.22% after the company's consolidated net profit declined 28% to Rs 25 crore despite 8% increase in revenue from operations to Rs 2797 crore in Q2 FY25. Usha Martin added 2.15% after the company reported 5.38% rise in consolidated net profit to Rs 109.72 crore in Q2 FY25 as against Rs 104.11 crore posted in Q1 FY25. Revenue from operations added 7.84% to Rs 891.17 crore in Q2 FY25 as against Rs 826.37 crore posted in Q1 FY25.Powered by Capital Market - Live

Revenue from operations increased 15.31% year on year (YoY) to Rs 5,589.3 crore in the quarter ended 30 September 2024. Profit before tax in second quarter of FY25 was at Rs 557.4 crore, up 47.07% from Rs 379 crore recorded in similar period last fiscal. The company's EBITDA grew by 30% YoY to Rs 816 crore in the September 2024 quarter. On segmental front, revenue from Healthcare Services was at Rs 2,920.4 crore (up 13.81% YoY), revenue from Digital Health & Pharmacy distribution was Rs 2,282.2 crore (up 17.31% YoY) and revenue from Retail Health & Diagnostics stood at Rs 403.9 crore (up 14.03% YoY) during the quarter. As on 30 September 2024, Apollo Hospitals had 7,994 operating beds across the network (excluding AHLL & managed beds). The overall occupancy for hospitals was at 73% vs 68% in the same period in the previous year, aided by a strong increase in patient flows. On half year basis the company's consolidated net profit soared 71.21% to Rs 684 crore in H1 FY25 as against Rs 399.5 crore posted in H1 FY24. However the company's revenue from operation rose 15.22% YoY to Rs 10,674.9 crore in H1 FY25. Dr. Prathap C. Reddy, founder & chairman, Apollo Hospitals Group said, 'One of our proudest achievements is our recent partnership with the Government of Tripura to provide free heart surgeries for children, underscoring our belief that healthcare should reach those who need it most, especially in underserved communities. Beyond expanding access, we are advancing medical technology with innovative treatments like water vapor thermotherapy for prostate care and robotic radiosurgery systems for cancer. These state-of-the-art solutions make procedures less invasive and reduce recovery time, resulting in better patient outcomes. We're also investing in the future of healthcare with the launch of our new research academy, which is focused on driving groundbreaking medical discoveries that will shape the next generation of treatments. Our priorities remain clear-enhancing patient care, prioritizing safety, and advancing medical science. The first half of FY25 has been an exciting time for us, marked by these major milestones aimed at extending the reach and impact of our healthcare services. Moving forward, our mission is simple: to push the boundaries of healthcare and ensure that everyone, regardless of where they live, has access to the best medical services. This is our promise, and we are committed to making it a reality. Apollo Hospitals Enterprise is a private sector healthcare provider. It owns and operates hospitals across the country. Powered by Capital Market - Live

Result Today: Mahindra & Mahindra(M&M), Lupin, RVNL, Trent, Shyam Metalics, Indian Hotels, Goldiam International, Gujarat State Petronet, Gujarat Alkalies and Chemicals, Happy Forgings, HIL, Indigo Paints, ITD Cementation India, Jagran Prakashan, Kennametal India, Linde India, AAVAS Financiers, Abbott India, Akzo Nobel India, Alembic Pharmaceuticals, Bajaj Electricals, Carysil, Clean Science and Technology, Cummins India, Emami, Escorts Kubota, Great Eastern Shipping Co will declare their result later today Stocks to Watch: Apollo Hospitals Enterprise reported 62.64% surge in consolidated net profit to Rs 378.8 crore in Q2 FY25 as against Rs 232.9 crore posted in Q2 FY24. Revenue from operations increased 15.31% year on year (YoY) to Rs 5,589.3 crore in the quarter ended 30 September 2024. Tata Steel reported net loss of Rs 759 crore in Q2 FY25 as compared with net loss of Rs 6,511 crore in Q2 FY24. Revenue fell 3.2% YoY to Rs 53,905 crore during the quarter. Sonata Software's consolidated net profit increased marginally 0.8% to Rs 106 crore in Q2 FY25 as compared with Rs 105.6 crore in Q1 FY25. Revenue declined 14.13% QoQ to Rs 2,170 crore in Q2 FY25. Power Grid Corporation of India's consolidated net profit increased marginally 0.31% to Rs 3,793 crore in Q2 FY25 as compared with Rs 3,781 crore in Q2 FY24. Revenue rose slightly higher 0.08% to Rs 11,277 crore in Q2 FY25 as compared with Rs 11,267 crore in Q2 FY24. Pricol's consolidated net profit jumped 36.36% to Rs 45 crore on 15.74% increase in revenue to Rs 669 crore in Q2 FY25 over Q2 FY24. Delta Corp's consolidated net profit declined 60.86% to Rs 27 crore on 27.97% decline in revenue to Rs 188 crore in Q2 FY25 over Q2 FY24.Powered by Capital Market - Live

Revenue from operations increased 15.31% year on year (YoY) to Rs 5,589.3 crore in the quarter ended 30 September 2024. Profit before tax in second quarter of FY25 was at Rs 557.4 crore, up 47.07% from Rs 379 crore recorded in similar period last fiscal. The company's EBITDA grew by 30% YoY to Rs 816 crore in the September 2024 quarter. On segmental front, revenue from Healthcare Services was at Rs 2,920.4 crore (up 13.81% YoY), revenue from Digital Health & Pharmacy distribution was Rs 2,282.2 crore (up 17.31% YoY) and revenue from Retail Health & Diagnostics stood at Rs 403.9 crore (up 14.03% YoY) during the quarter. As on 30 September 2024, Apollo Hospitals had 7,994 operating beds across the network (excluding AHLL & managed beds). The overall occupancy for hospitals was at 73% vs 68% in the same period in the previous year, aided by a strong increase in patient flows. On half year basis the company's consolidated net profit soared 71.21% to Rs 684 crore in H1 FY25 as against Rs 399.5 crore posted in H1 FY24. However the company's revenue from operation rose 15.22% YoY to Rs 10,674.9 crore in H1 FY25. Dr. Prathap C. Reddy, founder & chairman, Apollo Hospitals Group said, 'One of our proudest achievements is our recent partnership with the Government of Tripura to provide free heart surgeries for children, underscoring our belief that healthcare should reach those who need it most, especially in underserved communities. Beyond expanding access, we are advancing medical technology with innovative treatments like water vapor thermotherapy for prostate care and robotic radiosurgery systems for cancer. These state-of-the-art solutions make procedures less invasive and reduce recovery time, resulting in better patient outcomes. We're also investing in the future of healthcare with the launch of our new research academy, which is focused on driving groundbreaking medical discoveries that will shape the next generation of treatments. Our priorities remain clear-enhancing patient care, prioritizing safety, and advancing medical science. The first half of FY25 has been an exciting time for us, marked by these major milestones aimed at extending the reach and impact of our healthcare services. Moving forward, our mission is simple: to push the boundaries of healthcare and ensure that everyone, regardless of where they live, has access to the best medical services. This is our promise, and we are committed to making it a reality. Apollo Hospitals Enterprise is a private sector healthcare provider. It owns and operates hospitals across the country. The scrip added 0.05% to currently trade at Rs 6,974.70 on the BSE. Powered by Capital Market - Live

Net profit of Apollo Hospitals Enterprise rose 62.64% to Rs 378.80 crore in the quarter ended September 2024 as against Rs 232.90 crore during the previous quarter ended September 2023. Sales rose 15.32% to Rs 5589.30 crore in the quarter ended September 2024 as against Rs 4846.90 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales5589.304846.90 15 OPM %14.5912.95 - PBDT741.90540.50 37 PBT557.40377.10 48 NP378.80232.90 63 Powered by Capital Market - Live

Apollo Hospitals Enterprise will hold a meeting of the Board of Directors of the Company on 6 November 2024.Powered by Capital Market - Live

Revenue from operations increased 15.12% year on year (YoY) to Rs 5,085.6 crore in the quarter ended 30 June 2024. Profit before tax in first quarter of FY25 was at Rs 430 crore, up 59.26% from Rs 270 crore recorded in similar period last fiscal. EBITDA grew by 32.63% to Rs 675.1 crore in the June 2024 quarter as against Rs 509 crore posted in Q1 FY25. EBITDA margin improved to 13.3% in Q1 FY25 as compared to 11.5% registered in the corresponding quarter previous year. During the quarter, the company's revenue from Healthcare Services was at Rs 2,637.3 crore (up 14.98% YoY) and revenue from Digital Health & Pharmacy distribution was Rs 2,082.1 crore (up 15.33% YoY) and the revenue from Retail Health & Diagnostics stood at Rs 366.1 crore (up 14.87% YoY). As on 30 June 2024, Apollo Hospitals had 7,942 operating beds across the network (excluding AHLL & managed beds). The overall occupancy for hospitals was at 68% vs 62% in the same period in the previous year, aided by a strong increase in patient flows across hospitals with inpatient (IP) volume increasing by 11% and outpatient (OP) new registrations by 13%. Dr. Prathap C. Reddy, chairman, Apollo Hospitals Group said, 'In the first quarter of FY25, we have seen significant growth and improved the reach of our retail operations. As we continue our growth journey, we remain dedicated to advancing healthcare excellence, implementing innovative solutions, and improving access to the best healthcare services throughout India and beyond.' Apollo Hospitals Enterprise is a private sector healthcare provider. It owns and operates hospitals across the country.' The scrip rose 0.82% to currently trade at Rs 6,640.35 on the BSE. Powered by Capital Market - Live

Net profit of Apollo Hospitals Enterprise rose 83.19% to Rs 305.20 crore in the quarter ended June 2024 as against Rs 166.60 crore during the previous quarter ended June 2023. Sales rose 15.12% to Rs 5085.60 crore in the quarter ended June 2024 as against Rs 4417.80 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales5085.604417.80 15 OPM %13.2711.52 - PBDT607.40436.90 39 PBT430.00270.00 59 NP305.20166.60 83 Powered by Capital Market - Live

Apollo Hospitals Enterprise announced that the Annual General Meeting (AGM) of the company will be held on 30 August 2024.Powered by Capital Market - Live